red spot at injection site tirzepatide TrimRX Tirzepatide-Induced Injection Site Reaction |

Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States

The licensing of oral semaglutide provided a step forward in type 2 diabetes management for this group, and the publication of the SOUL study in 2025 reassured us that oral semaglutide could also offer cardiovascular benefit in those at highest risk

It costs $174.99/month

It is important they discuss the risks and benefits with their healthcare provider before initiating off-label use

Semaglutide helps both groups, just at different scales

It is being evaluated in Phase 3 trials for obesity and type 2 diabetes